La vendita allo scoperto per Theravance Biopharma dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Theravance Biopharma. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Theravance Biopharma (NASDAQ:TBPH) Azioni, Report sulle vendite allo scoperto

Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma Inc

<p>Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing&nbsp;nOH in patients with multiple system atrophy, which is currently ongoing.</p>


News

TBPH

Theravance To Present New Analyses Of Initial Phase 3 Program Of Ampreloxetine Supporting Selective And Differentiated Pharmacodynamic Profile At AAN Meeting

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   reiterates Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and maintains $15 price target.</p>


Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $15 Price Target

<p>Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.21) by 76.19 percent. This is a 70.59 percent increase over losses of $(0.17) per share from the same period last year.  The company reported quarterly sales of $18.75 million which beat the analyst consensus estimate of $17.09 million by 9.73 percent.  This is a 6.77 percent increase over sales of $17.57 million the same period last year.</p>


Earnings

Earnings Beats

Theravance Biopharma Q4 Adj EPS $(0.05) Beats $(0.21) Estimate, Sales $18.75M Beat $17.09M Estimate

AAOI

ABEV

ACAD

ACMR

ADTN

ALEC

AMBA

AMBC

AMSF

ARDT

ARHS

ARIS

ARKO

ASTE

ATEC

AVDX

AVNS

BATRA

BATRK

BBSI

BLMN

BXSL

BYND

CAPL

CDNA

CERT

CLDT

CLPT

COCO

COMM

CORT

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRGY

CSAN

CTRI

DHIL

DMRC

DOLE

DORM

EBAY

ECPG

EHTH

ENIC

ENOV

ERII

ESCA

ESTA

EVTC

FTAI

FWRD

GERN

GOGL

GSX Techedu Inc. American Depositary Shares

GOTU

GRBK

HCAT

HNST

IBTA

IMCR

Earnings Scheduled For February 26, 2025

WIIM

Theravance Biopharma shares are trading higher after the company reported better-than-expected Q3 sales results.

Guidance

Theravance Biopharma Sees FY24 R&D Expense $30M-$36M; Share-Based Compensation $18M-$22M; SG&A $45M-$55M.

<p>Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.23) by 13.04 percent.  The company reported quarterly sales of $16.900 million which beat the analyst consensus estimate of $15.344 million by 10.14 percent.  This is a 7.69 percent increase over sales of $15.693 million the same period last year.</p>


Earnings Misses

Theravance Biopharma Q3 2024 Adj. EPS $(0.26) Misses $(0.23) Estimate, Sales $16.900M Beat $15.344M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMPS

AMTX

APEI

AREB

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Biotech

General

Theravance Publishes Sub-Study 12-Week, Randomized, Registrational Revefenacin Phase 3 Trials For YUPELRI

<p>Across the recent three months, 4 analysts have shared their insights on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $12.25, with a high estimate of $15.00 and a low estimate of $9.00. A 18.33% drop is evident in the current average compared to the previous average price target of $15.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726488035_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Theravance Biopharma's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Marc Frahm</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Theravance Biopharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Theravance Biopharma compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Theravance Biopharma's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Theravance Biopharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TBPH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Theravance Biopharma analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Theravance Biopharma</h2>
<p>Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).</p>
<h3>Theravance Biopharma: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Theravance Biopharma displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>3.69%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Theravance Biopharma's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-115.94%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Theravance Biopharma's ROE excels beyond industry benchmarks, reaching <strong>-8.29%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.51%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.24</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unveiling 4 Analyst Insights On Theravance Biopharma

<p><strong>Theravance Biopharma, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) reported a second-quarter 2024 adjusted net loss of 13 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 9 cents per share. In the year-ago quarter, the company had reported a loss of 13 cents per share.</p>
<p>The reported loss excludes share-based compensation expense, non-cash impairment of long-lived assets, income tax expense and non-cash interest expense. Including these items, the company reported a loss of 34 cents per share in the second quarter.</p>
<p>Total revenues came in at $14.3 million, missing the Zacks Consensus Estimate of $16 million. Revenues, however, rose 4.4% year over year owing to increased collaboration revenues from partner <strong>Viatris</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtrs#NASDAQ">VTRS</a>).</p>
<h3>Quarter in Detail</h3>
<p>The top line fully comprised Viatris&#39; collaboration revenues in relation to Yupelri (revefenacin) sales.</p>
<p>Theravance and Viatris have collaborated for the development and commercialization of Yupelri.</p>
<p>Viatris and Theravance share U.S. profits and losses received in connection with the commercialization of Yupelri. While Viatris gets 65% of the profits, Theravance receives 35%. Viatris collaboration revenues include Theravance&#39;s 35% share of net sales of Yupelri, as well as its proportionate amount of the total shared costs incurred by the two companies.</p>
<p>VTRS recognizes product sales from Yupelri and also owns a stake in Theravance.</p>
<p>Shares of Theravance have declined 14.7% year to date compared with the industry&#39;s decline of 3.3%.</p>
<p><img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/41/73498.jpg?v=151316647" /></p>
<p>Image Source: Zacks Investment Research</p>
<p>Research and development expenses (excluding share-based compensation) totaled $8.8 million, up almost 17.3% from the year-ago quarter&#39;s level. Selling, general and administrative expenses (excluding share-based compensation) declined around 13.4% year over year to $12.9 million.</p>
<p>As of Jun 30, 2024, Theravance had cash, cash equivalents and marketable securities worth $96.1 million compared with $100 million as of Mar 31, 2024.</p>
<h3>2024 Guidance</h3>
<p>Theravance continues to expect adjusted R&amp;D expenses (excluding share-based compensation) in the $30-$36 million range. Adjusted SG&amp;A expenses (excluding share-based compensation) are projected between $45 million and $55 million.</p>
<p>TBPH continues to expect share-based compensation expenses of&nbsp;$18-$22 million in 2024.</p>
<p>For the remainder of 2024, TBPH now expects levels of both adjusted losses and cash burn to be the same as the first half of 2024. Earlier, the company expected to achieve breakeven in the second half of 2024 while expecting limited cash burn for the year.</p>
<h3>Pipeline Updates</h3>
<p>Theravance is developing an investigational candidate, ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor for the treatment of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy. The FDA has granted Orphan Drug designation to ampreloxetine for the given indication.</p>
<p>The company initiated the phase III CYPRESS study evaluating ampreloxetine for nOH MSA in the first quarter of 2024. The CYPRESS study is expected to complete patient enrollment by mid-2025, which was earlier expected to be completed by the second half of 2024. Top-line data from the same is expected almost six months after enrollment is completed. TBPH plans to submit regulatory filings for ampreloxetine if the study data is found to be positive.</p>
<div class="chart_embed">
<h3>Theravance Biopharma, Inc. Price, Consensus and EPS Surprise</h3>
<p><img alt="Theravance Biopharma, Inc. Price, Consensus and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/95/1722950875.png" style="height:265px; width:574px" title="" /></p>
<p>Theravance Biopharma, Inc. price-consensus-eps-surprise-chart | Theravance Biopharma, Inc. Quote</p>
</div>
<h3>Zacks Rank &amp; Stocks to Consider</h3>
<p>Theravance currently carries a Zacks Rank #3 (Hold).</p>
<p>Some better-ranked stocks in the healthcare sector are <strong>Halozyme Therapeutics, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/halo#NASDAQ">HALO</a>) and <strong>Repare Therapeutics Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rptx#NASDAQ">RPTX</a>), each sporting a Zacks Rank #1 (Strong Buy) at present.</p>
<p>In the past 60 days, estimates for Halozyme&#39;s 2024 earnings per share have improved from $3.69 to $3.90. Earnings per share estimates for 2025 have improved from $4.50 to $4.81. Year to date, shares of HALO have soared 40.9%.</p>
<p>HALO&#39;s earnings beat estimates in three of the trailing four quarters and met the same on the remaining occasion, the average surprise being 9.40%.</p>
<p>In the past 60 days, estimates for Repare Therapeutics&#39; 2024 loss per share have narrowed from $2.42 to $2.35. Loss per share estimates for 2025 have narrowed from $3.29 to $3.21. Year to date, shares of RPTX have plunged 57.2%.</p>
<p>RPTX&#39;s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 123.58%.</p>
<p><a href="https://www.zacks.com/stock/news/2317149/theravance-tbph-q2-loss-wider-than-expected-revenues-rise-y-y?cid=CS-BENZ-FT-analyst_blog|earnings_article-2317149">To read this article on Zacks.com click here.</a></p>


Penny Stocks

Small Cap

Markets

Trading Ideas

HALO

RPTX

VTRS

Theravance Q2 Loss Wider Than Expected, Revenues Rise Y/Y

<p>HC Wainwright &amp; Co.  analyst Douglas Tsao   maintains Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Buy and lowers the price target from $20 to $15.</p>


HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Lowers Price Target to $15

Theravance Biopharma shares are trading lower after the company reported mixed Q2 financial results. Also, Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $15 to $10.

<p>4 analysts have expressed a variety of opinions on Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $14.75, with a high estimate of $20.00 and a low estimate of $9.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.67%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722963640_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Theravance Biopharma by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marc Frahm</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Theravance Biopharma. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Theravance Biopharma compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Theravance Biopharma's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Theravance Biopharma's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TBPH/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Theravance Biopharma analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>About Theravance Biopharma</h2>
<p>Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).</p>
<h3>Financial Milestones: Theravance Biopharma's Journey</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Theravance Biopharma's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>39.22%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Theravance Biopharma's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-80.42%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Theravance Biopharma's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-5.58%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Theravance Biopharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-3.1%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Theravance Biopharma's debt-to-equity ratio is below the industry average at <strong>0.23</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma

<p>TD Cowen  analyst Marc Frahm   maintains Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) with a Hold and lowers the price target from $10 to $9.</p>


TD Cowen Maintains Hold on Theravance Biopharma, Lowers Price Target to $9

<p>Leerink Partners  analyst David Risinger   downgrades Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) from Outperform to Market Perform and lowers the price target from $15 to $10.</p>


Downgrades

Leerink Partners Downgrades Theravance Biopharma to Market Perform, Lowers Price Target to $10

<p>The Company continues to expect full year 2024 R&amp;D expenses of&nbsp;$30 million&nbsp;to&nbsp;$36 million&nbsp;and SG&amp;A expenses of&nbsp;$45 million&nbsp;to&nbsp;$55 million, in each case excluding share-based compensation.</p>
<p>The Company continues to expect full year share-based compensation expenses of&nbsp;$18 million&nbsp;to&nbsp;$22 million.</p>


Theravance Biopharma Now Expects FY24 Levels Of Both Non-GAAP Losses And Cash Burn To Be Similar To First Half Actuals 2024

<p>Theravance Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBPH#NASDAQ">TBPH</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.21) by 38.1 percent.  The company reported quarterly sales of $14.256 million which missed the analyst consensus estimate of $15.453 million by 7.75 percent.  This is a 3.69 percent increase over sales of $13.749 million the same period last year.</p>


Theravance Biopharma Q2 2024 Adj. EPS $(0.13) Beats $(0.21) Estimate, Sales $14.256M Miss $15.453M Estimate

Press Releases

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting

Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025

Comments

Theravance Biopharma

Vendite allo scoperto

Theravance Biopharma (NASDAQ:TBPH) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO